174 related articles for article (PubMed ID: 38186580)
41. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
[TBL] [Abstract][Full Text] [Related]
42. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
43. Integrated analysis reveals SMARCD1 is a potential biomarker and therapeutic target in skin cutaneous melanoma.
Chen J; Yu N; Ou S; Wang X; Li H; Zhu H
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11619-11634. PubMed ID: 37401939
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of B cells in cutaneous melanoma.
Selitsky SR; Mose LE; Smith CC; Chai S; Hoadley KA; Dittmer DP; Moschos SJ; Parker JS; Vincent BG
Genome Med; 2019 May; 11(1):36. PubMed ID: 31138334
[TBL] [Abstract][Full Text] [Related]
45. Prognostic and immune-related value of STK17B in skin cutaneous melanoma.
Shi X; Zhou Q; Huang B; Xia S; Jiang Y; Fang S; Lin J
PLoS One; 2022; 17(2):e0263311. PubMed ID: 35171924
[TBL] [Abstract][Full Text] [Related]
46. MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q; Zhang S; Zhang H; Sun J; Lu J; Wang G; Wang X
Int Immunopharmacol; 2023 Mar; 116():109783. PubMed ID: 36773567
[TBL] [Abstract][Full Text] [Related]
47. A Necroptosis-Related Gene Signature to Predict the Prognosis of Skin Cutaneous Melanoma.
Xie Y; Xu Z; Mei X; Shi W
Dis Markers; 2022; 2022():8232024. PubMed ID: 36438905
[TBL] [Abstract][Full Text] [Related]
48. The Identification of the Metabolism Subtypes of Skin Cutaneous Melanoma Associated With the Tumor Microenvironment and the Immunotherapy.
Yang R; Wang Z; Li J; Pi X; Gao R; Ma J; Qing Y; Zhou S
Front Cell Dev Biol; 2021; 9():707677. PubMed ID: 34458265
[TBL] [Abstract][Full Text] [Related]
49. Pattern Recognition Receptors (PRRs) in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma.
Zhao Q; Wang Q; Wang T; Xu J; Li T; Liu Q; Yao Q; Wang P
Front Immunol; 2021; 12():765615. PubMed ID: 34858419
[TBL] [Abstract][Full Text] [Related]
50. CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status.
Feng X; Zhang M; Wang B; Zhou C; Mu Y; Li J; Liu X; Wang Y; Song Z; Liu P
J Exp Clin Cancer Res; 2019 Aug; 38(1):361. PubMed ID: 31419991
[TBL] [Abstract][Full Text] [Related]
51. Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma.
Jia M; Liu C; Liu Y; Bao Z; Jiang Y; Sun X
J Pers Med; 2022 Dec; 13(1):. PubMed ID: 36675674
[TBL] [Abstract][Full Text] [Related]
52. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.
Pei L; Liu Y; Liu L; Gao S; Gao X; Feng Y; Sun Z; Zhang Y; Wang C
Mol Cancer; 2023 Feb; 22(1):29. PubMed ID: 36759842
[TBL] [Abstract][Full Text] [Related]
53. A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma.
Jiang L; Yang Y; Liu F; Ma M; Gao J; Sun L; Chen Y; Shen Z; Wu D
Front Cell Dev Biol; 2022; 10():859958. PubMed ID: 35399535
[No Abstract] [Full Text] [Related]
54. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
55. The role of NLRP3 in the prognosis and immune infiltrates of skin cutaneous melanoma (SKCM).
Wu S; Zang Q; Dai B
Transl Cancer Res; 2021 Apr; 10(4):1692-1702. PubMed ID: 35116494
[TBL] [Abstract][Full Text] [Related]
56. Machine learning-derived identification of tumor-infiltrating immune cell-related signature for improving prognosis and immunotherapy responses in patients with skin cutaneous melanoma.
Leng S; Nie G; Yi C; Xu Y; Zhang L; Zhu L
Cancer Cell Int; 2023 Sep; 23(1):214. PubMed ID: 37752452
[TBL] [Abstract][Full Text] [Related]
57. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
58. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients.
Wang X; Xiong H; Liang D; Chen Z; Li X; Zhang K
BMC Cancer; 2020 May; 20(1):378. PubMed ID: 32370744
[TBL] [Abstract][Full Text] [Related]
59. SMG7-AS1 as a prognostic biomarker and predictor of immunotherapy responses for skin cutaneous melanoma.
Xu X; Ju Y; Zhao X; Yang P; Zhu F; Fang B
Genomics; 2023 May; 115(3):110614. PubMed ID: 36931476
[TBL] [Abstract][Full Text] [Related]
60. Integrated analysis to reveal potential therapeutic targets and prognostic biomarkers of skin cutaneous melanoma.
Zhou X; Rong R; Xiong S; Song W; Ji D; Xia X
Front Immunol; 2022; 13():914108. PubMed ID: 36032150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
